Management of natural and added dietary phosphorus burden in kidney disease

A Cupisti, K Kalantar-Zadeh - Seminars in nephrology, 2013 - Elsevier
Phosphorus retention occurs from higher dietary phosphorus intake relative to its renal
excretion or dialysis removal. In the gastrointestinal tract the naturally existing organic …

Phosphate homeostasis and disorders

P Manghat, R Sodi… - Annals of clinical …, 2014 - journals.sagepub.com
Recent studies of inherited disorders of phosphate metabolism have shed new light on the
understanding of phosphate metabolism. Phosphate has important functions in the body and …

Vascular calcification mechanisms: updates and renewed insight into signaling pathways involved in high phosphate-mediated vascular smooth muscle cell …

N Abbasian - Biomedicines, 2021 - mdpi.com
Vascular calcification (VC) is associated with aging, cardiovascular and renal diseases and
results in poor morbidity and increased mortality. VC occurs in patients with chronic kidney …

Oral vitamin D3 supplementation increases serum fibroblast growth factor 23 concentration in vitamin D-deficient patients: a systematic review and meta-analysis

N Charoenngam, P Rujirachun, MF Holick… - Osteoporosis …, 2019 - Springer
Studies have suggested that vitamin D supplementation may increase serum fibroblast
growth factor 23 (FGF23) among vitamin D-deficient patients although the results were …

Ferric carboxymaltose in iron-deficient patients with hospitalized heart failure and reduced kidney function

IC Macdougall, P Ponikowski, AG Stack… - Clinical Journal of the …, 2023 - journals.lww.com
Background Reduced kidney function is common among patients with heart failure. In
patients with heart failure and/or kidney disease, iron deficiency is an independent predictor …

Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: A pooled analysis of clinical trials

GMC Rosano, K Kalantar‐Zadeh… - ESC heart …, 2023 - Wiley Online Library
Aims Iron deficiency is a common finding among patients with heart failure (HF) and is
associated with adverse outcomes, including decreased quality of life, increased risk of …

[HTML][HTML] Phosphate control: the next frontier in dialysis cardiovascular mortality

PA McCullough - Cardiorenal medicine, 2021 - karger.com
Background: Cardiovascular disease (CVD) is a major cause of death in patients with
chronic kidney disease (CKD) on dialysis. Mortality rates are still unacceptably high even …

Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and …

M Ota, M Takahata, T Shimizu, Y Kanehira… - Osteoporosis …, 2017 - Springer
This study showed that bisphosphonate was safe and effective for the treatment of bone
disorders in stage 4 chronic kidney disease (CKD) rats. Intermittent teriparatide therapy …

Uncovering specific taxonomic and functional alteration of gut microbiota in chronic kidney disease through 16S rRNA data

Y Zhang, W Zhong, W Liu, X Wang, G Lin… - Frontiers in Cellular …, 2024 - frontiersin.org
Introduction Chronic kidney disease (CKD) is worldwide healthcare burden with growing
incidence and death rate. Emerging evidence demonstrated the compositional and …

Phosphatemic index is a novel evaluation tool for dietary phosphorus load: A whole-foods approach

Y Narasaki, M Yamasaki, S Matsuura, M Morinishi… - Journal of Renal …, 2020 - Elsevier
Objective Dietary phosphorus (P) restriction is crucial to treat hyperphosphatemia and
reduce cardiovascular disease risk and mortality in patients with chronic kidney disease …